Intensity Modulated Radiation Therapy (IMRT): A New Promising Technology in Radiation Oncology
|
|
- Isaac Carson
- 6 years ago
- Views:
Transcription
1 Intensity Modulated Radiation Therapy (IMRT): A New Promising Technology in Radiation Oncology BIN S. TEH, SHIAO Y. WOO, E. BRIAN BUTLER Department of Radiology/Radiation Oncology, Baylor College of Medicine, Houston, Texas, USA Key Words. Intensity modulated radiation therapy Conformal radiotherapy SMART boost Central nervous system tumor Head and neck cancer Prostate cancer Reirradiation ABSTRACT Intensity modulated radiation therapy (IMRT) is a new technology in radiation oncology that delivers radiation more precisely to the tumor while relatively sparing the surrounding normal tissues. It also introduces new concepts of inverse planning and computer-controlled radiation deposition and normal tissue avoidance in contrast to the conventional trial-and-error approach. IMRT has wide application in most aspects of radiation oncology because of its ability to create multiple targets and multiple avoidance structures, to treat different targets simultaneously to different doses as well as to weight targets and INTRODUCTION Together with surgery and chemotherapy, radiotherapy plays an important role in oncology, both in the definitive and palliative aspects of treatment. Three major aspects of radiation oncology are potentially important advances in cancer treatment. The first is a multidisciplinary therapeutic approach with important clinical applications, the second is the progress in the physics and dosimetry of radiotherapy that has clinical ramification, and the third is genetic radiotherapy that will be translated to clinical practice [1]. Intensity modulated radiation therapy (IMRT) is the product of advances in the technology of radiotherapy to deliver radiation more precisely to the tumor while relatively limiting dose to the surrounding normal tissues. The purpose of this paper is to discuss the new concept of IMRT, its application in radiation oncology and potential benefits over conventional radiotherapy. IMRT A REVOLUTIONARY CONCEPT In radiotherapy the single most important limiting factor is the normal tissue radiation tolerance, and the objective of optimal radiotherapy is to deliver the maximum radiation dose to the avoidance structures according to their importance. By delivering radiation with greater precision, IMRT has been shown to minimize acute treatment-related morbidity, making dose escalation feasible which may ultimately improve local tumor control. IMRT has also introduced a new accelerated fractionation scheme known as SMART (simultaneous modulated accelerated radiation therapy) boost. By shortening the overall treatment time, SMART boost has the potential of improving tumor control in addition to offering patient convenience and cost savings. The Oncologist 1999;4: tumor while keeping the dose to the surrounding normal structures below tolerance [2]. To date this aim is achieved by the use of multiple treatment fields, choice of beam energies and modalities, weighting of different beams as well as the use of wedges and tissue compensators. In addition, two-dimensional customized blocks are routinely used to shield the normal structures. All of these conventional treatment-planning processes are approaches by trial and error. For example, a radiation oncologist will first place a radiation treatment field and then evaluate the dose. If the dose is not acceptable, a new field or other modification has to be made. This trial-and-error process has to be repeated until the optimal dose and coverage is achieved. This is time-consuming and sometimes no optimal plan can be reached. IMRT combines two advanced concepts to deliver 3D conformal radiation therapy: A) inverse treatment planning with optimization by computer and B) computer-controlled intensity modulation of the radiation beam during treatment [3]. Inverse Treatment Planning with Computer Optimization In contrast to the conventional trial-and-error approach, a radiation oncologist defines the tumor and the radiation dose Correspondence: E. Brian Butler, M.D., Baylor College of Medicine, One Baylor Plaza, 165B, Houston, Texas , USA. Telephone: ; Fax: ; ebutler@onramp.net Accepted for publication October 9, AlphaMed Press /99/$5.00/0 The Oncologist 1999;4:
2 434 Intensity Modulated Radiation Therapy for Cancer Treatment that he wants around the tumor. The computer, using a mathematical optimization technique known as simulated annealing, will determine the optimal treatment fields. In addition, one can also define where one does not want the deposition of radiation (e.g., dose-limiting critical surrounding normal tissues). Figure 1 shows a smiling face demonstrating how radiation can be deposited in almost any pattern. Computer-Controlled Intensity Modulation of the Radiation Beam During Treatment IMRT (NOMOS Peacock system; Sewickley, PA) has evolved from computer tomography (CT) concepts. A CT scan delivers uniform radiation exposure to the patient as it rotates around the patient s contour in a slice-by-slice fashion. Figure 1. Shows a smiling face demonstrating how many small beams of radiation can be deposited to produce the final uniform pattern. Computed tomography Due to varying attenuation among multiple tissues, a nonuniform radiation dose exits the patient and hits the detector. The detector feeds this information to the computer, which processes it to create the sliced scan images. The Peacock IMRT system, on the other hand, starts with the target volume, where it places a uniform, conformal dose around the tumor. The computer then backprojects through the patient s tissue to the linear accelerator source and finds the nonuniform radiation exposure that must be delivered by the linear accelerator to give this conformal dose pattern. The system, like the CT scan, uses a slice-by-slice, arc-rotation approach. The concept of the Peacock system is demonstrated in Figure 2. IMRT is a customized or individualized radiotherapy according to patient s location of tumor and anatomical structures, i.e., each patient has his or her own unique treatment plan. Blocks, compensators and wedges are obviated. With the availability of a powerful computer, planning time is short. Treatment delivery is also very efficient as there is no need for different energies of photons or mixed photon and electron beams. A special multileaf collimating system known as multileaf intensity modulating collimator (MIMiC) (Fig. 3) is used to deliver spatially nonuniform radiation exposure to the patient to create a relatively uniform dose distribution at the target. CONSIDERATIONS IN THE DELIVERY OF IMRT The more conformal a radiation treatment approach, the less error is allowed in patient set-up and treatment planning. In simpler terms, one cannot use conformal radiotherapy to treat a moving target, as the incidence of missing the target is very high! Also, small movements can result in Conformal therapy Projection Detectors Target Radiation source Radiation source Intensity modulator Figure 2. Demonstrates the concept of the Peacock system, an inverse planning system.
3 Teh, Woo, Butler 435 Figure 3. MIMiC (Multileaf Intensity Modulating Collimator), a special multileaf collimating system. significant deviations from calculated doses based on an instantaneous image. Thus, patient and organ movements are of crucial concern when delivering conformal radiation therapy. The ideal site to start IMRT is the brain where the central nervous system (CNS) tumors are encased in the cranium. The only factor is patient s movement that can be minimized by either the Peacock talon system (invasive fixation device) or a special reinforced mask (noninvasive immobilization device). The talon system uses two self-tapping skull screws/sockets attached to the skull. The talon body is then secured to the screws/sockets. The body is then rigidly fixed to support the structure on the treatment table to achieve good patient immobilization [4]. In addition to the above immobilization techniques, an intraoral stent or bite-block is used for organ immobilization when treating head and neck cancers. Oral stents also serve the purpose of normal tissue avoidance, e.g., protecting oral tongue in treating the cancers of the hard palate. Treating prostate cancers poses a challenge in both patient and organ movements. Due to anatomic and physical constraint, an invasive fixation technique for the pelvis was found not to be feasible. Prior experience with immobilization techniques enabled the development of a fiducial system linked to a treatment box. The patient lies prone in an evacuated beanbag that conforms both to the patient s body contour and the treatment box. Each patient has Figure 4. Shows multiple brain metastases alone treated simultaneously with IMRT. his own box with the fitted beanbag throughout the treatment. This has helped in solving the problem of patient movement. The next problem is the previously well-documented movement of the prostate itself [5]. This problem is significant with regard to using IMRT to treat prostate cancer. Prostate motion during radiotherapy can lead to underdosing the target (prostate) and/or overdosing critical normal structures (rectum and bladder). A rectal catheter with an inflated balloon was developed to minimize the prostate motion. IMRT can then be delivered with more confidence. To date, only a limited attempt has been made to use IMRT in treating lung cancer, as it has proved difficult to immobilize lung and chest wall movement satisfactorily due to respiratory motion. APPLICATION OF IMRT AND ITS POTENTIAL ADVANTAGES Once the problem of patient and organ motion is resolved, IMRT can be applied to various tumors at various sites, either for definitive or palliative treatment intent. To Create Multiple Targets Multiple treatment targets can be created and treated at the same time. A good example is multiple brain metastases. For patients who have prior whole brain radiotherapy and need boost irradiation, or patients with metastatic radioresistant tumors, e.g., renal cell carcinoma or melanoma, multiple brain metastases can be treated simultaneously to high-dose radiation while other parts of the brain are avoided as shown in Figure 4. This has the benefit of decreasing treatment-related CNS toxicity.
4 436 Intensity Modulated Radiation Therapy for Cancer Treatment Besides creating multiple targets of the same origin, IMRT also enables the planning and treatment of multiple targets of different origins. A good example is in head and neck cancers as shown in Figure 5. The primary target (red) includes all palpable and imaging documented abnormal tumor and lymph nodes. The secondary target (purple) includes all at-risk subclinical disease sites, e.g., all draining lymphatics, perineural routes, etc. Different targets can then be treated simultaneously with different fraction sizes and different total doses. This has significant implication in radiobiological control of gross versus subclinical disease. Another example is using IMRT to treat two completely unrelated tumors simultaneously as demonstrated in a patient with pituitary adenoma and chemodectoma (Fig. 6). To Create Multiple Critical Avoidance Normal Structures There are many critical normal structures surrounding the targets, especially when treating head and neck or brain tumors. These structures include optic nerves and chiasm, lens, lacrimal glands, salivary glands, mandible, temporal lobes, brain stem and spinal cord. These structures usually have lower radiation tolerance, much lower than the tumoricidal radiation dose. Typical radiation thresholds used in these avoidance structures are shown in Table 1. IMRT allows the creation of these avoidance structures on the treatment plan as well as the designation of their respective radiation thresholds. This has led to the concept of conformal avoidance, i.e., limiting the radiation to the surrounding structures below the designated threshold limit (Fig. 5). Weightings In addition to conformal treatment and avoidance, the Peacock IMRT system allows differential weightings on both targets and avoidance structures (Table 2). Generally the target (tumor) is weighted more than the avoidance structures. However, in cases where a tumor surrounds a critical structure, e.g., optic chiasm, and the patient does not want to accept the treatment complication of losing his vision, the avoidance structure is then weighted more than the target. The ability of differential weighting has increased the versatility of IMRT and can be used to tailor to patient s needs and wishes. New Accelerated Fractionation Scheme With the advent of IMRT and its capability to treat multiple targets simultaneously to different doses, a new accelerated fractionation scheme is introduced. It is known as simultaneous modulated accelerated radiation therapy (SMART) boost [4]. SMART boost can be applied to various sites including head and neck, brain and prostate. The principle is to treat two different targets with different fraction sizes to different total doses. A good example is the Figure 5. Primary target (red) includes all palpable and imaging documented abnormal tumor and lymph nodes. Secondary target (purple) includes all atrisk subclinical disease sites, e.g., all draining lymphatics. It illustrates sparing of mandible, spinal cord and parotids. Figure 6. Patient with pituitary adenoma and chemodectoma two targets treated simultaneously with IMRT. treatment of head and neck cancers. Accelerated repopulation of tumor clonogens during conventional fractionated radiotherapy has been recognized as an important cause of treatment failure in head and neck cancers, especially if the overall
5 Teh, Woo, Butler 437 Table 1. Normal structures in the head and neck with their assigned radiation thresholds Normal structures Radiation thresholds Normal structures Radiation thresholds (Gy) (Gy) Brain stem 50 Optic chiasm 45 Lacrimal glands 30 Parotid (ipsilateral) 35 Lens 12 Parotid (contralateral) 25 Retina 45 Spinal cord 40 Optic nerves 45 Mandible 58 Table 2. Radiation deposition and avoidance Number of fractions 25 over 37 days (inclusive) Planning parameter Target Prescribed dose Total Daily Target weight Target 1 6,000 cgy 240 cgy 1.0 Target 2 5,000 cgy 200 cgy 1.0 Nontarget structures Maximum dose Target weight Mandible 5,800 cgy 1.0 Right parotid gland 2,500 cgy 1.0 Left parotid gland 2,500 cgy 1.0 Brain stem 5,000 cgy 0.1 Spinal cord 4,000 cgy 0.5 Table 3. Various accelerated treatment schedules Radiotherapy Dose Total dose Overall schedules fractions (cgy) duration Standard fractionation 35 fractions 200 cgy daily = 7,000 7 weeks ***CAIR 35 fractions 200 cgy daily = 7,000 5 weeks ***CHART 36 fractions 150 cgy TID = 5, days ***MGH accelerated split course 42 fractions 160 cgy BID = 6,720 6 weeks MDACC concomitant boost 30 fractions 180 cgy daily + 12 fractions 150 cgy daily = 7,200 6 weeks SMART boost technique 25 fractions 240 cgy (Target 1) = 6, fractions 200 cgy (Target 2) = 5,000 5 weeks ***Continuous accelerated radiotherapy. ***Continuous hyperfractionated accelerated radiotherapy. ***Massachusetts General Hospital. M.D. Anderson Cancer Center. Simultaneous modulated accelerated radiation therapy. treatment time is prolonged. Both laboratory and clinical data [6-8] support this hypothesis. The reduction of overall treatment time has the potential for improving tumor control by minimizing tumor clonogen regeneration. Various purely accelerated treatment schedules have been used, e.g., Polish Trial (CAIR) [9], CHART [10], Massachusetts General Hospital accelerated split course [11] and M.D. Anderson Concomitant Boost [12] (Table 3). These trials have suggested improved tumor control. By applying SMART boost by the use of IMRT, the primary target (palpable and imaging documented gross tumors and lymph nodes) and the secondary targets (at risk microscopic disease sites, e.g., draining
6 438 Intensity Modulated Radiation Therapy for Cancer Treatment Table 4. Various CNS tumors treated with IMRT Types of tumor n of patients A) Pediatric Medulloblastoma 11 Craniopharyngioma 10 Astrocytoma 6 Ependymoma 5 Germ cell tumor 3 Brain stem glioma 2 Ganglioglioma 2 B) Adult Meningioma 22 Pituitary adenoma 14 Neuroma 4 Total 79 lymphatics) are treated simultaneously to total doses of 60 Gy and 50 Gy, respectively over five weeks. Daily fraction sizes are 2.4 Gy and 2.0 Gy, respectively. As it is completed in five weeks compared to the conventional seven weeks, it is an accelerated scheme. SMART has the benefit of delivering only once-daily treatments, five days a week compared to other accelerated schemes usually involving twice or three-times-a-day or treating over the weekend. It is cost saving and offers patient convenience. More importantly, it has the radiobiological advantage of overcoming the accelerated repopulation of clonogens during radiation therapy that may lead to improved treatment outcome. CLINICAL OUTCOME THE BAYLOR COLLEGE OF MEDICINE EXPERIENCE More than 700 patients have been treated with IMRT at the Baylor College of Medicine since March 1994 to date. Four major subsets were presented and discussed. These include: A) CNS; B) head and neck; C) prostate, and D) previously irradiated patients. CNS Both pediatric and adult benign and malignant brain tumors have been treated with IMRT. Table 4 shows various CNS tumors treated with IMRT. Eleven patients with medulloblastoma received IMRT as a posterior fossa boost after the initial craniospinal irradiation, while the remaining 68 patients were irradiated with IMRT for the full course. Total prescribed doses ranged from 36 Gy to 64 Gy. Noninvasive immobilization was used in 35 patients and invasive immobilization was used in the other 45 patients. Median follow-up was 24 months. Figure 7 shows an axial plan of a patient with infratentorial ependymoma. The patient had gross total resection followed by full course IMRT. Temporal lobes and cranial nerve VIII are two important avoidance normal structures. With the capability of conformal avoidance by IMRT, the mean doses to temporal lobes and CN VIII are 21.7 Gy and 18.7 Gy, respectively, much below their tolerance threshold. Figure 8 shows an axial plan of a pituitary adenoma treated with IMRT. It illustrates the sparing of optic chiasm, temporal lobes, orbits and brain stem. Figure 7. Shows an axial plan of a patient with infratentorial ependymoma (purple), sparing CN VIII (blue). Figure 8. Shows an axial plan of a pituitary adenoma (red) treated with IMRT. It illustrates the sparing of optic chiasm (turquoise), temporal lobes (blue), orbits, and brain stem (green). Treatment-related toxicity was limited to mild headache in ten patients with two patients requiring steroids. Two patients with meningioma had symptoms from persistent peritumoral edema that was present before radiotherapy, requiring an increase in the steroid dose. Three patients had local scalp asymptomatic erythema. None of the patients
7 Teh, Woo, Butler 439 with invasive immobilization developed any infection at local wound sites. Two patients with optic nerve sheath meningioma have reported improvement in vision. Four patients (medulloblastoma, brain stem glioma, ganglioglioma and recurrent malignant meningioma) showed progression of disease. The remaining 76 patients (median follow-up of 30 months) showed no progression thus far. Head and Neck Cancers Twenty patients with primary head and neck cancers (Table 5) were treated with IMRT using the SMART boost technique with parotid preservation [4]. The treatment fields Table 5. Tumor site encompassed two simultaneous targets with primary target Tumor site n of patients Nasopharynx 3 including palpable and imaging detected disease and sec- Paranasal sinus 1 Oral cavity 1 ondary target including areas Oropharynx 12 at risk for microscopic disease, Larynx 3 e.g., lymphatic compartments. AJCC stage n of patients Daily fractions of 2.4 Gy and 2 I 0 Gy were prescribed to the primary and secondary targets to II 2 III 7 a total dose of 60 Gy and 50 IV 10 Gy, respectively. The overall NA 1 treatment course was over five weeks (daily treatment) rather than the usual seven weeks (daily treatment) or the more-than-daily treatment in other accelerated schemes. With the IMRT inverse planning system, we were able to limit the radiation dose to the parotid glands. For midline tumors the parotids were limited to 25 Gy. For a unilateral tumor the ipsilateral parotid was limited to 35 Gy and the contralateral gland to 25 Gy. Figure 5 shows an axial treatment plan of an oropharyngeal primary treated with SMART boost. It demonstrates two targets and sparing of parotid glands, mandible and spinal cord. Radiation Therapy Oncology Group (RTOG) acute toxicity grading criteria were used to evaluate surrounding normal tissue effects. Subjective salivary function was also assessed. Tumor response was evaluated by clinical examination, CT or magnetic resonance imaging (MRI) at periodic follow-up. Sixteen of 20 (80%) patients completed the treatment within 40 days. Two patients took up to 50 days to complete the treatment because of acute toxicity while two other patients completed the treatment in more than 50 days due to noncompliance rather than treatment-related side effects. Four separate organ systems were assessed using RTOG acute radiation morbidity scoring criteria [13]. Sixteen patients (80%) had RTOG grade 3 mucositis while ten patients (50%) had grade 3 pharyngitis. All patients recovered well after completion of radiotherapy. Encouragingly, more than half of the patients (55%) had grade 1 or less toxicity with the salivary gland; no patient had higher than grade 2 toxicity [4]. As xerostomia is a subjective report of symptom, the patients were asked to grade this symptom (none, mild, moderate and severe or complete). Eleven patients (55%) reported mild or no mouth dryness. Nine patients had moderate symptoms but none reported severe or complete xerostomia. Only one patient with moderate xerostomia was prescribed with pilocarpine. Time to relief of xerostomia varied from one to six months. A completely normal food intake was observed in seven patients. Initial tumor response to SMART boost using IMRT is shown in Table 6. Nineteen patients (95%) had a complete response (CR) while one patient had a partial response (PR). Median follow-up was six months. Two of the 19 patients with local regional CR Table 6. Head and neck cancers treated with SMART boost tumor response Follow-up Range Mean Median were found to have lung metastases at follow-up. There was no local regional recurrence or marginal miss. Prostate Cancer Fifty men aged 56 to 82 with a mean of 70.8 years were included in the study. Clinical stages ranged from T1c to T3a. Median Gleason combined score was 6.5 (4-9). Mean pretreatment prostate-specific antigen (PSA) was 11.8 ( ). All patients had negative metastatic work-up including chest x-ray, bone scan and CT of pelvis. Twenty-five (50%) patients had hormonal manipulation prior to and during radiotherapy. Patients treated with IMRT were prescribed a dose of 70 Gy in 35 fractions over days. This is compared to the only randomized trial in this dose range, i.e., 70 Gy (conventional in 35 fractions over days) and 78 Gy (six-field conformal in 39 fractions over days) [14]. Patients were immobilized in a prone position in an evacuated beanbag contained in a box. Rectal balloon was used daily to minimize prostate movement. Patients treated with the conventional and six-field conformal radiotherapy were in supine treatment position without rectal balloon immobilization. The RTOG scoring system was used to assess acute toxicity. Median follow-up was 5.5 months (1 to 12 months). Figure 9 shows an axial treatment plan of prostate cancer treated with IMRT. It illustrates well how use of the rectal balloon minimized the prostate motion as well as the highly conformal radiation dose coverage of tumor sparing 2-20 months 6.9 months 6 months Response to treatment CR 19 (including two patients with local CR but had lung metastases) PR - 1
8 440 Intensity Modulated Radiation Therapy for Cancer Treatment Figure 9. Shows an axial treatment plan of prostate cancer treated with IMRT. It illustrates how the rectal balloon minimizes the prostate motion as well as the highly conformal radiation dose coverage of prostate gland sparing the rectum. Table 7. Acute GU and lower GI toxicity secondary to radiotherapy for prostate cancer a comparison Total patients GU-RTOG grade GI-RTOG grade n (%) Conventional 30 (100) 2 (6.7) 12 (40.0) 13 (43.3) 4 (13.3) 7 (23.3) 18 (60.0) (3 pts [10.0] > grade 2) (1 pt [3.3] > grade 2) 6-field conformal 30 (100) 2 (6.7) 17 (56.7) 9 (30.0) 5 (16.7) 4 (13.3) 20 (66.7) (2 pts [6.7] > grade 2) (1 pt [3.3] > grade 2) IMRT 50 (100) 26 (52.0) 9 (18.0) 15 (30.0) 37 (74.0) 6 (12.0) 7 (14.0) the rectum. Mean doses to prostate, seminal vesicles, rectum and bladder were 75.8 Gy, 73.7 Gy, 34.2 Gy and 23.3 Gy, respectively. Although the prescribed dose for patients treated with IMRT was 70 Gy, the mean dose to the prostate was 75.8 Gy. There is dose inhomogeneity when the IMRT dosimetry is reviewed. At our institution we have used equivalent uniform dose (EUD) for reporting in order to give a more accurate delivered dose representation. EUD is found to be very similar to the mean dose in the treatment of prostate cancer. Thus, a higher dose is delivered with IMRT when compared to that of conventional treatment for prostate cancer despite the same prescribed dose. A mean dose of approximately 76 Gy over 35 fractions delivers a daily fraction size of approximately 2.17 Gy. Moderate dose escalation is desired as there is evidence to suggest dose response [15]. Higher radiation dose delivered with 3D conformal radiotherapy has been shown to improve treatment outcome of prostate cancer [15]. This is also a form of an accelerated fractionation scheme as 76 Gy is delivered over seven weeks in 35 fractions. The higher daily fraction size of 2.17 Gy is also well tolerated by patients as shown by the acute toxicity profile. Acute genitourinary (GU) and gastrointestinal (GI) toxicity are shown in Table 7. There was a statistical difference (p < 0.001) for both GU and lower GI grade 0, 1, 2 toxicity between the IMRT and conventional or six-field conformal group. There was no grade 3 or higher toxicity noted in the IMRT group. Of note was the very low incidence of grade 2 GI toxicity in the IMRT group (14%) compared to the conventional (60%) and the six-field conformal group (66.7%) [16]. It is too early to assess late toxicity or biochemical control (especially since 50% of the patients received androgen
9 Teh, Woo, Butler 441 ablation). However, there already is an emerging trend suggesting that PSA nadir was reached early post-radiotherapy compared to nadir after conventional treatment. To date no patient has had a biochemical failure (three consecutive rises in PSA). Recurrent Tumor Previously Irradiated Ten patients with recurrent carcinoma in the head and neck were reirradiated to provide further local control as well as symptom palliation. Five patients had recurrent carcinoma of nasopharynx while the remaining consisted of recurrent carcinoma involving maxillary sinus, nasal cavity, medial canthus, oropharynx and posterior pharyngeal wall. All patients received prior radiotherapy ranging from 30 Gy to 67 Gy. They were all referred to our center as it was felt that no further radiation could be delivered safely to the local recurrence with conventional radiotherapy. Additional radiation was delivered with IMRT. The dose ranged from 16 Gy to 66 Gy. Toxicity was graded using RTOG morbidity scores, and tumor response was evaluated by clinical examination, CT and/or MRI. Follow-ups ranged from 2 to 12 months. All patients were able to complete planned reirradiation at the scheduled time frame. There was no grade 3 or higher RTOG toxicity in mucosa, pharynx, skin or salivary glands that required split from treatment. All patients achieved the aim of palliation of local symptoms such as pain, epistaxis or discomfort. Quality of life has improved during and on completion of radiotherapy. Only half of the patients showed no progression of disease at the last follow-up. THE COST OF SMART BOOST Medicare allowable charge of SMART boost was compared to conventional fractionated radiotherapy and accelerated radiotherapy (concomitant boost) in the treatment of head and neck cancer as shown in Table 8. This includes both professional and technical charges. Total Medicare allowable charge for SMART boost is $7,000 compared to $8,600 (conventional) and $9,400 (concomitant boost) [4]. CONCLUSION Both theoretical and clinical data have shown the benefits of IMRT especially in decreasing acute treatment-related toxicity in either definitive or palliative reirradiated cases. This is made possible by delivering the radiation to the tumor with greater precision while relatively sparing the surrounding normal tissues. Minimizing toxicity is of major significance in all patients especially in treating childhood cancers. Quality of life is a very important issue for long-term survivors. Early tumor response and control are also very encouraging. With the lower treatment-related toxicity, dose escalation with IMRT is feasible in the future. This may have further implications for improvement of tumor control and cure. SMART boost with parotid preservation, a novel accelerated fractionation scheme with IMRT, is clinically feasible, radiobiologically beneficial and offers patient convenience. It is hoped to decrease the incidence of debilitating xerostomia and improve outcome of patients with head and neck cancers. Larger cohort and longer-term follow-up are warranted to demonstrate the impact of IMRT on improved tumor control and decreased long-term morbidity. IMRT holds promise in radiation oncology in the new century. More clinical data are needed to confirm the potential promise. Table 8. Medicare allowable charges: a comparison among different radiotherapy regimens for the treatment of head and neck cancer Radiotherapy schedules Medicare allowable charges (including both professions and technical charges) Conventional $8,600 Concomitant boost $9,400 SMART boost $7,000 REFERENCES 1 Hellman S, Weichselbaum RR. Radiation oncology. JAMA 1996;275: Woo SY, Sanders M, Grant WH et al. Does the Peacock have anything to do with radiation therapy? Int J Radiat Oncol Biol Phys 1994;29: Purdy, JA. Intensity modulated radiation therapy (editorial). Int J Radiat Oncol Biol Phys 1996;35: Butler EB, Teh BS, Grant WH et al. SMART (Simultaneous Modulated Radiation Therapy) boost a new accelerated fractionation schedule for the treatment of head and neck cancer with intensity modulated radiotherapy. Int J Radiat Oncol Biol Phys 1999;45: Ten-Haken RK, Forman JD, Heimburger DK et al. Treatment planning issues related to prostate movement in response to differential filling of the rectum and bladder. Int J Radiat Oncol Biol Phys 1991;20: Withers HR, Taylor JMG, Macejewski B. The hazard of accelerated tumor clonogen repopulation during radiation therapy. Acta Oncol 1988;27: Peters LJ, Ang KK, Mames Jr HD. Accelerated fractionation in the radiation treatment of head and neck cancer. Acta Oncol 1988;27: Barton MB, Keane TJ, Gadalla T et al. The effect of treatment time and treatment interruption on tumour control following
10 442 Intensity Modulated Radiation Therapy for Cancer Treatment radical radiation therapy of laryngeal cancer. Radiat Ther Oncol 1992;23: Maciejewski B, Skladowski K, Pilecki B et al. Randomized clinical trial on accelerated 7 days per week fractionation in radiotherapy for head and neck cancer: preliminary report on acute toxicity. Radiother Oncol 1996;40: Sanders MI, Dische S, Grosch EJ et al. Experience with CHART. Int J Radiat Oncol Biol Phys 1991;21: Wang CC. Improved local control for advanced oropharyngeal carcinoma following twice daily radiation therapy. Am J Clin Oncol 1985;8: Ang KK, Peters LJ, Weber RS et al. Concomitant boost radiotherapy schedules in the treatment of carcinoma of the oropharynx and nasopharynx. Int J Radiat Oncol Biol Phys 1990;19: Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) (editorial). Int J Radiat Oncol Biol Phys 1995;31: Pollack A, Zagars GK, Starkschall G et al. Conventional vs. conformal radiotherapy for prostate cancer: preliminary results of dosimetry and acute toxicity. Int J Radiat Oncol Biol Phys 1996;34: Zelefsky MJ, Leibel SA, Kutcher GJ et al. Three-dimensional conformal radiotherapy and dose escalation: where do we stand? Semin Radiat Oncol 1998;8: Teh BS, Uhl BM, Augspurger ME et al. Intensity modulated radiotherapy (IMRT) for localized prostate cancer: preliminary results of acute toxicity compared to conventional and six field approach. Int J Radiat Oncol Biol Phys 1998;42(suppl 1):219.
Evaluation of Whole-Field and Split-Field Intensity Modulation Radiation Therapy (IMRT) Techniques in Head and Neck Cancer
1 Charles Poole April Case Study April 30, 2012 Evaluation of Whole-Field and Split-Field Intensity Modulation Radiation Therapy (IMRT) Techniques in Head and Neck Cancer Abstract: Introduction: This study
More informationNCCN GUIDELINES ON PROTON THERAPY (AS OF 4/23/18) BONE (Version , 03/28/18)
BONE (Version 2.2018, 03/28/18) NCCN GUIDELINES ON PROTON THERAPY (AS OF 4/23/18) Radiation Therapy Specialized techniques such as intensity-modulated RT (IMRT); particle beam RT with protons, carbon ions,
More informationIntensity Modulated Radiation Therapy (IMRT)
Intensity Modulated Radiation Therapy (IMRT) Policy Number: Original Effective Date: MM.05.006 03/09/2004 Line(s) of Business: Current Effective Date: HMO; PPO 06/24/2011 Section: Radiology Place(s) of
More informationIntensity Modulated Radiation Therapy (IMRT)
Intensity Modulated Radiation Therapy (IMRT) Policy Number: Original Effective Date: MM.05.006 03/09/2004 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 03/01/2015 Section: Radiology
More informationIMRT - the physician s eye-view. Cinzia Iotti Department of Radiation Oncology S.Maria Nuova Hospital Reggio Emilia
IMRT - the physician s eye-view Cinzia Iotti Department of Radiation Oncology S.Maria Nuova Hospital Reggio Emilia The goals of cancer therapy Local control Survival Functional status Quality of life Causes
More informationIntensity Modulated Radiation Therapy (IMRT)
Intensity Modulated Radiation Therapy (IMRT) Policy Number: Original Effective Date: MM.05.006 03/09/2004 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 05/01/2017 Section: Radiology
More informationProtocol of Radiotherapy for Head and Neck Cancer
106 年 12 月修訂 Protocol of Radiotherapy for Head and Neck Cancer Indication of radiotherapy Indication of definitive radiotherapy with or without chemotherapy (1) Resectable, but medically unfit, or high
More informationCorporate Medical Policy
Corporate Medical Policy Intensity Modulated Radiation Therapy (IMRT) of Head and Neck File Name: Origination: Last CAP Review: Next CAP Review: Last Review: intensity_modulated_radiation_therapy_imrt_of_head_and_neck
More informationProtons for Head and Neck Cancer. William M Mendenhall, M.D.
Protons for Head and Neck Cancer William M Mendenhall, M.D. Protons for Head and Neck Cancer Potential Advantages: Reduce late complications via more conformal dose distributions Likely to be the major
More informationProtocol. Intensity-Modulated Radiation Therapy (IMRT): Central Nervous System Tumors
Intensity-Modulated Radiation Therapy (IMRT): Central Nervous (80159) Medical Benefit Effective Date: 03/01/14 Next Review Date: 03/15 Preauthorization No Review Dates: 07/12, 07/13, 03/14 The following
More informationPage 1. Helical (Spiral) Tomotherapy. UW Helical Tomotherapy Unit. Helical (Spiral) Tomotherapy. MVCT of an Anesthetized Dog with a Sinus Tumor
Helical (Spiral) Tomotherapy Novel Clinical Applications of IMRT Linac Ring Gantry CT Detector X-Ray Fan Beam Binary Multileaf Collimator Binary MLC Leaves James S Welsh, MS, MD Department of Human Oncology
More informationEfficient SIB-IMRT planning of head & neck patients with Pinnacle 3 -DMPO
Investigations and research Efficient SIB-IMRT planning of head & neck patients with Pinnacle 3 -DMPO M. Kunze-Busch P. van Kollenburg Department of Radiation Oncology, Radboud University Nijmegen Medical
More informationMANAGEMENT OF CA HYPOPHARYNX
MANAGEMENT OF CA HYPOPHARYNX GENERAL TREATMENT RECOMMENDATIONS BASED ON HYPOPHARYNX TUMOR STAGE For patients presenting with early-stage definitive radiotherapy alone or voice-preserving surgery are viable
More informationThis LCD recognizes these two distinct treatment approaches and is specific to treatment delivery:
National Imaging Associates, Inc. Clinical guidelines STEREOTACTIC RADIOSURGERY (SRS) AND STEREOTACTIC BODY RADIATION THERAPY (SBRT) CPT4 Codes: 77371, 77372, 77373 LCD ID Number: L33410 J-N FL Responsible
More informationNew Technologies for the Radiotherapy of Prostate Cancer
Prostate Cancer Meyer JL (ed): IMRT, IGRT, SBRT Advances in the Treatment Planning and Delivery of Radiotherapy. Front Radiat Ther Oncol. Basel, Karger, 27, vol. 4, pp 315 337 New Technologies for the
More informationCorporate Medical Policy
Corporate Medical Policy Intensity-Modulated Radiation Therapy (IMRT) of the Prostate File Name: Origination: Last CAP Review: Next CAP Review: Last Review: intensity_modulated_radiation_therapy_imrt_of_the_prostate
More informationEvaluation of Three-dimensional Conformal Radiotherapy and Intensity Modulated Radiotherapy Techniques in High-Grade Gliomas
1 Carol Boyd Comprehensive Case Study July 11, 2013 Evaluation of Three-dimensional Conformal Radiotherapy and Intensity Modulated Radiotherapy Techniques in High-Grade Gliomas Abstract: Introduction:
More informationHelical Tomotherapy Experience. TomoTherapy Whole Brain Head & Neck Prostate Lung Summary. HI-ART TomoTherapy System. HI-ART TomoTherapy System
The Challenges Associated with Differential Dose Delivery using IMRT Chester Ramsey, Ph.D. Director of Medical Physics Thompson Cancer Center Knoxville, Tennessee, U.S.A Collaborators Chester Ramsey, Ph.D.
More informationTreatment of exceptionally large prostate cancer patients with low-energy intensity-modulated photons
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, VOLUME 7, NUMBER 4, FALL 2006 Treatment of exceptionally large prostate cancer patients with low-energy intensity-modulated photons Mei Sun and Lijun Ma a University
More informationdoi: /s (03)
doi:10.1016/s0630-3016(03)00093-2 Int. J. Radiation Oncology Biol. Phys., Vol. 56, No. 1, pp. 136 144, 2003 Copyright 2003 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/03/$ see front
More informationIntensity modulated radiotherapy (IMRT) for treatment of post-operative high grade glioma in the right parietal region of brain
1 Carol Boyd March Case Study March 11, 2013 Intensity modulated radiotherapy (IMRT) for treatment of post-operative high grade glioma in the right parietal region of brain History of Present Illness:
More informationFirst, how does radiation work?
Hello, I am Prajnan Das, Faculty Member in the Department of Radiation Oncology at The University of Texas MD Anderson Cancer Center. We are going to talk today about some of the basic principles regarding
More informationOriginal Date: April 2016 Page 1 of 7 FOR CMS (MEDICARE) MEMBERS ONLY
National Imaging Associates, Inc. Clinical guidelines STEREOTACTIC RADIATION THERAPY: STEREO RADIOSURGERY (SRS) AND STEREOTACTIC BODY RADIATION THERAPY (SBRT) CPT4 Codes: Please refer to pages 5-6 LCD
More informationHigh-precision Radiotherapy
High-precision Radiotherapy a report by Professor Cai Grau and Dr Morten Hoyer Department of Oncology, Aarhus University Hospital, Denmark DOI: 10.17925/EOH.2005.0.0.40 Professor Cai Grau Dr Morten Hoyer
More informationCorporate Medical Policy
Corporate Medical Policy Intensity Modulated Radiation Therapy (IMRT) of Abdomen and File Name: Origination: Last CAP Review: Next CAP Review: Last Review: intensity_modulated_radiation_therapy_imrt_of_abdomen_and_pelvis
More informationPRIOR AUTHORIZATION Prior authorization is recommended and obtained via the online tool for participating providers.
Medical Coverage Policy Intensity-Modulated Radiotherapy: Central Nervous System Tumors EFFECTIVE DATE: 02 15 2016 POLICY LAST UPDATED: 09 05 2017 OVERVIEW Radiotherapy (RT) is an integral component in
More informationRadiation Oncology MOC Study Guide
Radiation Oncology MOC Study Guide The following study guide is intended to give a general overview of the type of material that will be covered on the Radiation Oncology Maintenance of Certification (MOC)
More informationPRINCIPLES OF RADIATION ONCOLOGY
PRINCIPLES OF RADIATION ONCOLOGY Ravi Pachigolla, MD Faculty Advisor: Anna Pou, MD The University of Texas Medical Branch Department of Otolaryngology Grand Rounds Presentation January 5, 2000 HISTORY
More informationHead and Neck Cancer: Altered Fractionation Schedules
Head and Neck Cancer: Altered Fractionation Schedules M.I. SAUNDERS Marie Curie Research Wing, Centre for Cancer Treatment, Mount Vernon Hospital, Northwood, Middlesex, United Kingdom Key Words. Head and
More informationRadiation Oncology Study Guide
Radiation Oncology Study Guide For the Initial CertificationQualifying (Computer-Based) Examination General and Radiation Oncology This examination is designed to assess your understanding of the entire
More informationMeasurement of Dose to Critical Structures Surrounding the Prostate from. Intensity-Modulated Radiation Therapy (IMRT) and Three Dimensional
Measurement of Dose to Critical Structures Surrounding the Prostate from Intensity-Modulated Radiation Therapy (IMRT) and Three Dimensional Conformal Radiation Therapy (3D-CRT); A Comparative Study Erik
More informationA STUDY OF PLANNING DOSE CONSTRAINTS FOR TREATMENT OF NASOPHARYNGEAL CARCINOMA USING A COMMERCIAL INVERSE TREATMENT PLANNING SYSTEM
doi:10.1016/j.ijrobp.2004.02.040 Int. J. Radiation Oncology Biol. Phys., Vol. 59, No. 3, pp. 886 896, 2004 Copyright 2004 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/04/$ see front
More informationProtocol. Intensity-Modulated Radiotherapy: Central Nervous System Tumors
Intensity-Modulated Radiotherapy: Central Nervous System (80159) Medical Benefit Effective Date: 07/01/17 Next Review Date: 03/18 Preauthorization No Review Dates: 07/12, 07/13, 03/14, 03/15, 03/16, 03/17,
More informationHead and Neck Service
Head and Neck Service University of California, San Francisco, Department of Radiation Oncology Residency Training Program Head and Neck and Thoracic Service Educational Objectives for PGY-5 Residents
More informationPotential benefits of intensity-modulated proton therapy in head and neck cancer van de Water, Tara Arpana
University of Groningen Potential benefits of intensity-modulated proton therapy in head and neck cancer van de Water, Tara Arpana IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's
More informationRADIO- AND RADIOCHEMOTHERAPY OF HEAD AND NECK TUMORS. Zoltán Takácsi-Nagy PhD Department of Radiotherapy National Institute of Oncology, Budapest 1.
RADIO- AND RADIOCHEMOTHERAPY OF HEAD AND NECK TUMORS Zoltán Takácsi-Nagy PhD Department of Radiotherapy National Institute of Oncology, Budapest 1. 550 000 NEW PATIENTS/YEAR WITH HEAD AND NECK CANCER ALL
More informationState of the Art Radiotherapy for Pediatric Tumors. Suzanne L. Wolden, MD Memorial Sloan-Kettering Cancer Center
State of the Art Radiotherapy for Pediatric Tumors Suzanne L. Wolden, MD Memorial Sloan-Kettering Cancer Center Introduction Progress and success in pediatric oncology Examples of low-tech and high-tech
More informationUPDATE ON RADIOTHERAPY
1 Miriam Kleiter UPDATE ON RADIOTHERAPY Department for Companion Animals and Horses, Plattform Radiooncology and Nuclear Medicine, University of Veterinary Medicine Vienna Introduction Radiotherapy has
More informationProtocol of Radiotherapy for Breast Cancer
107 年 12 月修訂 Protocol of Radiotherapy for Breast Cancer Indication of radiotherapy Indications for Post-Mastectomy Radiotherapy (1) Axillary lymph node 4 positive (2) Axillary lymph node 1-3 positive:
More informationProstate Cancer. 3DCRT vs IMRT : Hasan Murshed
Prostate Cancer 3DCRT vs IMRT : the second debate Hasan Murshed Take home message IMRT allows dose escalation. Preliminary data shows IMRT technique improves cancer control while keeping acceptable morbidity
More informationTo Reduce Hot Dose Spots in Craniospinal Irradiation: An IMRT Approach with Matching Beam Divergence
SCIENCE & TECHNOLOGY To Reduce Hot Dose Spots in Craniospinal Irradiation: An IMRT Approach with Matching Beam Divergence Alburuj R. Rahman*, Jian Z. Wang, Dr. Z. Huang, Dr. J. Montebello Department of
More informationClinically Proven Metabolically-Guided TomoTherapy SM Treatments Advancing Cancer Care
Clinically Proven Metabolically-Guided TomoTherapy SM Treatments Advancing Cancer Care Institution: San Raffaele Hospital Milan, Italy By Nadia Di Muzio, M.D., Radiotherapy Department (collaborators: Berardi
More informationA VMAT PLANNING SOLUTION FOR NECK CANCER PATIENTS USING THE PINNACLE 3 PLANNING SYSTEM *
Romanian Reports in Physics, Vol. 66, No. 2, P. 401 410, 2014 A VMAT PLANNING SOLUTION FOR NECK CANCER PATIENTS USING THE PINNACLE 3 PLANNING SYSTEM * M. D. SUDITU 1,2, D. ADAM 1,2, R. POPA 1,2, V. CIOCALTEI
More informationPEDIATRIC ORBITAL TUMORS RADIOTHERAPY PLANNING
PEDIATRIC ORBITAL TUMORS RADIOTHERAPY PLANNING ANATOMY ANATOMY CONT ANATOMY CONT. ANATOMY CONT. EYE OF A CHILD Normal tissue tolerance doses (in conventional #) TD 5/5 TD 50/5 Endpoint Gy Gy Optic nerve
More informationThe technique of craniospinal irradiation of paediatric patients in supine position
The technique of craniospinal irradiation of paediatric patients in supine position Pavel Šlampa 1, Zuzana Seneklova 1, Jiri Simicek 1, Renata Soumarova 1, Petr Burkon 2, Ludmila Burianova 2 1 Masaryk
More informationRole of adaptive radiation therapy for pediatric patients with diffuse pontine glioma
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, VOLUME 12, NUMBER 2, spring 2011 Role of adaptive radiation therapy for pediatric patients with diffuse pontine glioma Chris Beltran, a Saumya Sharma, and Thomas
More informationChapter 7 General conclusions and suggestions for future work
Chapter 7 General conclusions and suggestions for future work Radiation therapy (RT) is one of the principle treatment modalities for the management of cancer. In recent decades, advances in the radiation
More informationA TREATMENT PLANNING STUDY COMPARING VMAT WITH 3D CONFORMAL RADIOTHERAPY FOR PROSTATE CANCER USING PINNACLE PLANNING SYSTEM *
Romanian Reports in Physics, Vol. 66, No. 2, P. 394 400, 2014 A TREATMENT PLANNING STUDY COMPARING VMAT WITH 3D CONFORMAL RADIOTHERAPY FOR PROSTATE CANCER USING PINNACLE PLANNING SYSTEM * D. ADAM 1,2,
More informationIntensity Modulated Radiation Therapy (IMRT): Central Nervous System Tumors. Original Policy Date
MP 8.01.36 Intensity Modulated Radiation Therapy (IMRT): Central Nervous System Tumors Medical Policy Section Therapy Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date Created with literature
More informationBrain Tumor Treatment
Scan for mobile link. Brain Tumor Treatment Brain Tumors Overview A brain tumor is a group of abnormal cells that grows in or around the brain. Tumors can directly destroy healthy brain cells. They can
More informationRadiotherapy physics & Equipments
Radiotherapy physics & Equipments RAD 481 Lecture s Title: An Overview of Radiation Therapy for Health Care Professionals Dr. Mohammed Emam Vision :IMC aspires to be a leader in applied medical sciences,
More informationTomoTherapy. Michelle Roach CNC Radiation Oncology Liverpool Hospital CNSA. May 2016
TomoTherapy Michelle Roach CNC Radiation Oncology Liverpool Hospital CNSA May 2016 TomoTherapy The Facts Greek Tomo = slice Advanced form of IMRT 3D computerised tomography (CT) imaging immediately prior
More informationDemands and Perspectives of Hadron Therapy
Demands and Perspectives of Hadron Therapy Alexander Lin, M.D. Assistant Professor University of Pennsylvania Direction of Operations Roberts Proton Therapy Center Disclosures Teva Pharmaceuticals: Advisory
More informationIMRT - Intensity Modulated Radiotherapy
IMRT - Intensity Modulated Radiotherapy Advanced product in the RT technology Aims to deliver radiation more precisely to the tumor, while relatively limiting dose to the surrounding normal tissues 7 position
More informationHead and Neck Service
Head and Neck Service University of California, San Francisco, Department of Radiation Oncology Residency Training Program Head and Neck and Thoracic Service Educational Objectives for PGY-3 Residents
More informationStereotactic Radiosurgery and Stereotactic Body Radiation Therapy
Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Policy Number: Original Effective Date: MM.05.008 05/12/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 11/20/2015
More informationStereotactic Radiosurgery. Extracranial Stereotactic Radiosurgery. Linear accelerators. Basic technique. Indications of SRS
Stereotactic Radiosurgery Extracranial Stereotactic Radiosurgery Annette Quinn, MSN, RN Program Manager, University of Pittsburgh Medical Center Using stereotactic techniques, give a lethal dose of ionizing
More informationAMERICAN BRAIN TUMOR ASSOCIATION. Proton Therapy
AMERICAN BRAIN TUMOR ASSOCIATION Proton Therapy ACKNOWLEDGEMENTS ABOUT THE AMERICAN BRAIN TUMOR ASSOCIATION Founded in 1973, the American Brain Tumor Association (ABTA) was the first national nonprofit
More informationPrinciple of Radiation Therapy
Principle of Radiation Therapy Janjira Petsuksiri, M.D. Division of Radiation Therapy Faculty of Medicine Siriraj Hospital Basic sciences for residents Aug 11, 2010 Outlines Basic Radiation physics Basic
More informationStereotactic Radiosurgery and Stereotactic Body Radiation Therapy
Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Policy Number: Original Effective Date: MM.05.008 05/12/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 04/01/2015
More informationRadiotherapy in feline and canine head and neck cancer
Bettina Kandel Like surgery radiotherapy is usually a localized type of treatment. Today it is more readily available for the treatment of cancer in companion animals and many clients are well informed
More informationDepartment of Radiotherapy & Nuclear Medicine, National Cancer Institute, Cairo University, Cairo, Egypt.
Original article Res. Oncol. Vol. 12, No. 1, Jun. 2016:10-14 Dosimetric comparison of 3D conformal conventional radiotherapy versus intensity-modulated radiation therapy both in conventional and high dose
More informationStereotactic Radiosurgery and Stereotactic Body Radiation Therapy
Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Policy Number: Original Effective Date: MM.05.008 05/12/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 04/01/2017
More informationORIGINAL ARTICLE GAMMA KNIFE STEREOTACTIC RADIOSURGERY FOR SALIVARY GLAND NEOPLASMS WITH BASE OF SKULL INVASION FOLLOWING NEUTRON RADIOTHERAPY
ORIGINAL ARTICLE GAMMA KNIFE STEREOTACTIC RADIOSURGERY FOR SALIVARY GLAND NEOPLASMS WITH BASE OF SKULL INVASION FOLLOWING NEUTRON RADIOTHERAPY James G. Douglas, MD, MS, 1,2 Robert Goodkin, MD, 1,2 George
More informationA Comparison of IMRT and VMAT Technique for the Treatment of Rectal Cancer
A Comparison of IMRT and VMAT Technique for the Treatment of Rectal Cancer Tony Kin Ming Lam Radiation Planner Dr Patricia Lindsay, Radiation Physicist Dr John Kim, Radiation Oncologist Dr Kim Ann Ung,
More informationHelical Tomotherapy: An Innovative Technology and Approach to Radiation Therapy
Technology in Cancer Research & Treatment ISSN 1533-0346 Volume 1, Number 4, August (2002) Adenine Press (2002) Helical Tomotherapy: An Innovative Technology and Approach to Radiation Therapy www.tcrt.org
More informationInternational Multispecialty Journal of Health (IMJH) ISSN: [ ] [Vol-3, Issue-9, September- 2017]
Dosimetric evaluation of carcinoma nasopharynx using Volumetric Modulated Arc Therapy (VMAT): An institutional experience from Western India Dr. Upendra Nandwana 1, Dr. Shuchita Pathak 2, Dr. TP Soni 3,
More informationA Patient s Guide to SRS
A Patient s Guide to SRS Stereotactic Radiosurgery 230 Nebraska St. Sioux City, IA 51101 NOTES 230 Nebraska St. Sioux City, IA 51101 Contents page Introduction 1 SRS and how it works 2 The technology involved
More informationDisclosures. Overview 8/3/2016. SRS: Cranial and Spine
SRS: Cranial and Spine Brian Winey, Ph.D. Department of Radiation Oncology Massachusetts General Hospital Harvard Medical School Disclosures Travel and research funds from Elekta Travel funds from IBA
More informationSarcoma and Radiation Therapy. Gabrielle M Kane MB BCh EdD FRCPC Muir Professorship in Radiation Oncology University of Washington
Sarcoma and Radiation Therapy Gabrielle M Kane MB BCh EdD FRCPC Muir Professorship in Radiation Oncology University of Washington Objective: Helping you make informed decisions Introduction Process Radiation
More informationHead & Neck Contouring
Head & Neck Contouring Presented by James Wheeler, MD Center for Cancer Care Goshen, IN 46526 September 12, 2014 Special Thanks to: Spencer Boulter, Director of Operations (AAMD) Adam Moore, RT(T), CMD
More informationHead & Neck Clinical Sub Group. Network Agreed Imaging Guidelines for UAT and Thyroid Cancer. Measure Nos: 11-1C-105i & 11-1C-106i
Greater Manchester, Lancashire & South Cumbria Strategic Clinical Network & Senate Head & Neck Clinical Sub Group Network Agreed Imaging Guidelines for UAT and Thyroid Cancer Measure Nos: 11-1C-105i &
More informationJOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, VOLUME 6, NUMBER 2, SPRING 2005
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, VOLUME 6, NUMBER 2, SPRING 2005 Advantages of inflatable multichannel endorectal applicator in the neo-adjuvant treatment of patients with locally advanced
More informationLong-term parotid gland function after radiotherapy
Parotid gland sparing radiotherapy, P.M. Braam Chapter 2 Long-term parotid gland function after radiotherapy Pètra M. Braam 1, Judith M. Roesink 1, Marinus A. Moerland 1, Cornelis P.J. Raaijmakers 1, Maria
More informationPractice teaching course on head and neck cancer management
28-29 October 2016 - Saint-Priest en Jarez, France Practice teaching course on head and neck cancer management IMPROVING THE PATIENT S LIFE LIFE THROUGH MEDICAL MEDICAL EDUCATION EDUCATION www.excemed.org
More informationDescription. Section: Therapy Effective Date: July 15, 2015 Subsection: Original Policy Date: September 13, 2012 Subject: Page: 1 of 10
Last Review Status/Date: June 2015 Page: 1 of 10 Description Radiotherapy (RT) is an integral component in the treatment of many brain tumors, both benign and malignant. Intensity-modulated radiation therapy
More informationRadiotherapy and tumours in veterinary practice: part one
Vet Times The website for the veterinary profession https://www.vettimes.co.uk Radiotherapy and tumours in veterinary practice: part one Author : Aleksandra Marcinowska, Jane Dobson Categories : Companion
More informationOPTIMIZATION OF COLLIMATOR PARAMETERS TO REDUCE RECTAL DOSE IN INTENSITY-MODULATED PROSTATE TREATMENT PLANNING
Medical Dosimetry, Vol. 30, No. 4, pp. 205-212, 2005 Copyright 2005 American Association of Medical Dosimetrists Printed in the USA. All rights reserved 0958-3947/05/$ see front matter doi:10.1016/j.meddos.2005.06.002
More informationTOMOTERAPIA in Italia: Esperienze a confronto
TOMOTERAPIA in Italia: Esperienze a confronto BARD 20 novembre 2010 L esperienza di Reggio Emilia Testa collo Alessandro Muraglia Reasons for the use of tomotherapy: - Complex tumor geometry and proximity
More informationPalliative radiotherapy in lung cancer
New concepts and insights regarding the role of radiation therapy in metastatic disease Umberto Ricardi University of Turin Department of Oncology Radiation Oncology Palliative radiotherapy in lung cancer
More informationTreatment Planning Evaluation of Volumetric Modulated Arc Therapy (VMAT) for Craniospinal Irradiation (CSI)
Treatment Planning Evaluation of Volumetric Modulated Arc Therapy (VMAT) for Craniospinal Irradiation (CSI) Tagreed AL-ALAWI Medical Physicist King Abdullah Medical City- Jeddah Aim 1. Simplify and standardize
More informationMick Spillane. Medical. Intensity-Modulated Radiotherapy for Sinonasal Tumors
Mick Spillane Medical Formatted: Left Intensity-Modulated Radiotherapy for Sinonasal Tumors F Division of Radiotherapy, Department of Oncology (I. M., L. V., W. D. N.), and Division of Head and Neck Surgery,
More informationClinical Commissioning Policy Proposition: Proton Beam Therapy for Cancer of the Prostate
Clinical Commissioning Policy Proposition: Proton Beam Therapy for Cancer of the Prostate Reference: NHS England B01X09 First published: March 2016 Prepared by NHS England Specialised Services Clinical
More informationOriginal Article. Teyyiba Kanwal, Muhammad Khalid, Syed Ijaz Hussain Shah, Khawar Nadeem
Original Article Treatment Planning Evaluation of Sliding Window and Multiple Static Segments Technique in Intensity Modulated Radiotherapy for Different Beam Directions Teyyiba Kanwal, Muhammad Khalid,
More informationFlattening Filter Free beam
Dose rate effect in external radiotherapy: biology and clinic Marta Scorsetti, M.D. Radiotherapy and Radiosurgery Dep., Istituto Clinico Humanitas, Milan, Italy Brescia October 8th/9th, 2015 Flattening
More informationDefining Target Volumes and Organs at Risk: a common language
Defining Target Volumes and Organs at Risk: a common language Eduardo Rosenblatt Section Head Applied Radiation Biology and Radiotherapy (ARBR) Section Division of Human Health IAEA Objective: To introduce
More informationIGRT Solution for the Living Patient and the Dynamic Treatment Problem
IGRT Solution for the Living Patient and the Dynamic Treatment Problem Lei Dong, Ph.D. Associate Professor Dept. of Radiation Physics University of Texas M. D. Anderson Cancer Center Houston, Texas Learning
More informationKlinikleitung: Dr. Kessler Dr. Kosfeld Dr. Tassani-Prell Dr. Bessmann. Radiotherapy in feline and canine head and neck cancer.
Radiotherapy in feline and canine head and neck cancer Bettina Kandel Like surgery radiotherapy is usually a localized type of treatment. Today it is more readily available for the treatment of cancer
More informationAndrew K. Lee, MD, MPH Associate Professor Department tof fradiation Oncology M.D. Anderson Cancer Center
Proton Therapy for Prostate Cancer Andrew K. Lee, MD, MPH Associate Professor Department tof fradiation Oncology M.D. Anderson Cancer Center Seungtaek Choi, MD Assistant Professor Department tof fradiation
More informationCorporate Medical Policy
Corporate Medical Policy Intensity Modulated Radiation Therapy (IMRT) of the Chest File Name: Origination: Last CAP Review: Next CAP Review: Last Review: intensity_modulated_radiation_therapy_imrt_of_the_chest
More informationThe Role of Radiotherapy in Metastatic Breast Cancer. Shilpen Patel MD, FACRO Associate Professor Departments of Radiation Oncology and Global Health
The Role of Radiotherapy in Metastatic Breast Cancer Shilpen Patel MD, FACRO Associate Professor Departments of Radiation Oncology and Global Health Indications for Palliative Pain Control Radiation Bone
More informationDosimetric Comparison of Intensity-Modulated Radiotherapy versus 3D Conformal Radiotherapy in Patients with Head and Neck Cancer
Dosimetric Comparison of Intensity-Modulated Radiotherapy versus 3D Conformal Radiotherapy in Patients with Head and Neck Cancer 1- Doaa M. AL Zayat. Ph.D of medical physics, Ayadi-Al Mostakbl Oncology
More informationOutcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer
Clinical Urology Post-radiotherapy Prostate Biopsy for Recurrent Disease International Braz J Urol Vol. 36 (1): 44-48, January - February, 2010 doi: 10.1590/S1677-55382010000100007 Outcomes Following Negative
More informationRola brachyterapii w leczeniu wznów nowotworów języka i dna jamy ustnej. The role of brachytherapy in recurrent. oral cavity
Rola brachyterapii w leczeniu wznów nowotworów języka i dna jamy ustnej The role of brachytherapy in recurrent tumours of the tongue and fundus of the oral cavity Janusz Skowronek, MD, PhD, Ass. Prof.
More informationProstate immobilization using a rectal balloon
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, VOLUME 3, NUMBER 1, WINTER 2002 Prostate immobilization using a rectal balloon John. E. McGary,* Bin S. Teh, E. Brian Butler, and Walter Grant, III Department
More informationACR TXIT TM EXAM OUTLINE
ACR TXIT TM EXAM OUTLINE Major Domain Sub-Domain 1 Statistics 1.1 Study design 1.2 Definitions of statistical terms 1.3 General interpretation & analysis 1.4 Survival curves 1.5 Specificity/sensitivity
More informationStatistical Analysis and Volumetric Dose for Organ at Risk of Prostate Cancer
The African Review of Physics (2013) 8:0063 477 Statistical Analysis and Volumetric Dose for Organ at Risk of Prostate Cancer F. Assaoui¹,*, A. Bazine² and T. Kebdani³ ¹ Medical Physics Unit, Radiotherapy
More informationWhat is head and neck cancer? How is head and neck cancer diagnosed and evaluated? How is head and neck cancer treated?
Scan for mobile link. Head and Neck Cancer Head and neck cancer is a group of cancers that start in the oral cavity, larynx, pharynx, salivary glands, nasal cavity or paranasal sinuses. They usually begin
More informationNational System for Incident Reporting in Radiation Therapy (NSIR-RT) Taxonomy
Canadian Partnership for Quality Radiotherapy (CPQR) National System for Incident Reporting in Radiation Therapy (NSIR-RT) National System for Incident Reporting in Radiation Therapy (NSIR-RT) Taxonomy
More informationPotential benefits of intensity-modulated proton therapy in head and neck cancer van de Water, Tara Arpana
University of Groningen Potential benefits of intensity-modulated proton therapy in head and neck cancer van de Water, Tara Arpana IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's
More information